You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 61 - 70 of 8495 results
  1. A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT The serious unmet need to address the excessive mortality observed in patients with Acute Respiratory Distress Syndrome (ARDS) has been brought sharply into focus by the current COVID-19 pandemic. In this R-44 application, Aqualung Therapeutics will address this therapeutic gap by utilizing a novel, humanized monoclonal antibody, ALT-100 mAb, which binds/neutralizes a novel ARDS target, e ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Sequencing the Mono-Methylated Derivatives of Cytidine

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 172

    Project Summary The goal of this project is to develop a prototype sequencing platform and the associated methodology capable of directly sequencing the mono-methylated derivatives of cytosine. Recently, LC-MS/MS methods to assess the presence of the mono-methylated isomers of cytosine, i.e., 5-methylcytosine (m5C), 4-methylcytidine (m4C), 3- methylcytidine (m3C), 2`-O-methylcytidine (Cm), as well ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease

    SBC: APTUS BIOSCIENCES LLC            Topic: NIA

    Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild andmoderate Alzheimer’s disease Aptus Biosciences, LLCBharat Gawande SummaryToday, 6.2 million Americans are living with Alzheimer’s disease (AD), resulting in $355 billion in annual medical care costs. As the US population over age 65 grows, the number of Americans living with AD is expected to increase to ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. SUD-t Map: A Big Data Digital Platform to Identify and Characterize SUD Treatment Opportunities to Address Health Disparities

    SBC: S-3 RESEARCH LLC            Topic: NIDA

    1.a. PROJECT SUMMARY/ABSTRACT The proposed project will address a preeminent public health challenge that is acute and immediate: developing innovative commercial digital solutions to positively affect fundamental risk factors associated with health disparities and social determinants of health (SDOH) experienced by communities afflicted with substance use disorder (SUD). With an alarming 81,000 o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Selective actin remodeling of sensory neurons for acute pain management

    SBC: Neurocarrus Inc.            Topic: 106

    PROJECT SUMMARY There is an urgent need for new approaches to treat acute human pain without the risk of Substance Use Disorders (SUDs). The most effective approved pain pharmaceuticals, including narcotics and anesthetics, are not neuron-specific and consequently suffer from off-target effects like addiction, inhibition of motor neurons, and destruction of the surrounding tissues. When inflammati ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures

    SBC: BIOVINC, LLC            Topic: NIAID

    ABSTRACTBone fracture is a large medical problem in the US, with 6 million presentations each year, resulting in very large cost burdens. In addition, the total burden of fractures in the US is growing due to the aging of the population and increases in osteoporosis. Some of these fractures do not heal properly, largely due to infections resulting in high additional costs and morbidity in this sub ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma

    SBC: VIVREON BIOSCIENCES LLC            Topic: NHLBI

    Vivreon Biosciences, LLC 4940 Carroll Canyon Rd., Ste. 110San Diego, CA 92121 milton@vivreonbiosciences.com NHLBI PA-21-259 Project Summary Severe asthma is a potentially lethal disease that is not fully controlled by anti-inflammatory small molecule or biologic therapies. Recent evidence indicates that severe asthma patients exhibit substantial airway remodeling (AR) where the epithelial, goblet ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction

    SBC: INFLAMMATIX, INC.            Topic: NHLBI

    ABSTRACT Chest pain, the main symptom of acute myocardial infarction (AMI), accounts for ~5% of all emergency department (ED) visits. In the absence of ECG abnormalities, diagnostic gold standard for AMI relies on serial troponin (cTn) measurements which are inconclusive in 20-40% of patients, requiring additional testing and prolonged observation in the ED. A missed diagnosis of AMI without prope ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease

    SBC: ONCTERNAL THERAPEUTICS, INC.            Topic: 106

    PROJECT SUMMARY Kennedy’s disease, also known as spinobulbar muscular atrophy (SBMA), is a progressive neurodegenerative disease caused by genetic polyglutamine expansion in the N-terminal domain (NTD) of the androgen receptor (AR). Recent research has shown that the mutant AR protein misfolds, aggregates, and abnormally interacts with other proteins, leading to androgen- dependent lower motor n ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government